


What Is Claimed Is:

1. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an anti-hepatitis virus effective amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:

5



(I)

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

10 wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl.

2. The method of claim 1, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

3. The method of claim 2, wherein R is nonyl.

4. The method of claim 1, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

09/249,220

Mueller et al / pd. 2/12/98 (pau)

5. The method of claim 4, wherein R is nonyl.
6. The method of claim 5, wherein said alkanoyl is butanoyl.
7. The method of claim 1, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:
- N*-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- 15 *N*-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate
- 20 *N*-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
- N*-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
- N*-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
- N*-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
- 25 *N*-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
- N*-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
- N*-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
- N*-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

30

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

45

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

50

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;


0
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

55 *N*-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
60 *N*-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
 N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
 N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
75 *N*-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

8. The method of claim 1, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate,

persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

9. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an antiviral composition comprising an antiviral effective amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl.

10. The method of claim 9, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

11. The method of claim 10, wherein R is nonyl.

12. The method of claim 9, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

13. The method of claim 12, wherein R is nonyl.
14. The method of claim 13, wherein said alkanoyl is butanoyl.
15. The method of claim 9, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:
- N*-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- 15 *N*-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N*-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate
- N*-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
- N*-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
- 20 *N*-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
- N*-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
- N*-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
- N*-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
- N*-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
- 25 *N*-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

5
10
15
20
25

30

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

45

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

50

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

35
36
37
38
39
40
41
42
43
44
45
46
47
48
49


55 *N*-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
60 *N*-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
 N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
 N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
75 *N*-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

5

16. The method of claim 9, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate,

persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

17. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an antiviral composition consisting essentially of an antiviral effective amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



(I)

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl.

18. The method of claim 17, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

19. The method of claim 18, wherein R is nonyl.

20. The method of claim 17, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

21. The method of claim 20, wherein R is nonyl.
22. The method of claim 21, wherein said alkanoyl is butanoyl.

23. The method of claim 17, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

- N*-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
15 *N*-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
20 *N*-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
25 *N*-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
30 *N*-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
35 *N*-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
40 *N*-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
45 *N*-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
50 *N*-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
55 *N*-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

0922222222 0922222222
35
40
45

45


50

55 *N*-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
60 *N*-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
65 *N*-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
70 *N*-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
 N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
75 *N*-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

24. The method of claim 17, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate,

persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

25. A method for treating a hepatitis virus infection in a mammal, consisting essentially of administering to said mammal an antiviral effective amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



(I)

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

10 wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl.

26. The method of claim 25, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

27. The method of claim 26, wherein R is nonyl.

28. The method of claim 25, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

29. The method of claim 28, wherein R is nonyl.

30. The method of claim 29, wherein said alkanoyl is butanoyl.

31. The method of claim 25, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

5

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

10
11
12
13
14
15

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

20

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

25

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

30 *N*-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

60


N-(9-methyldeecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

75

32. The method of claim 25, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

5

10 33. A method for treating a hepatitis virus infection in a mammal, consisting essentially of administering to said mammal an antiviral effective amount of an antiviral compound consisting essentially of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



(I)

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl.

20 34. The method of claim 33, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

35. The method of claim 34, wherein R is nonyl.

36. The method of claim 33, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

37. The method of claim 36, wherein R is nonyl.

38. The method of claim 37, wherein said alkanoyl is butanoyl.

39. The method of claim 33, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

- 5 *N*-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate
 N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

5

10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95

20

25

30 *N*-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
35 *N*-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
50 *N*-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
55 *N*-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

SEARCHED
INDEXED
SERIALIZED
FILED
APR 20 1993

45


50

55

60 *N*-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
65 *N*-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
 N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
 N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
 N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.
75

40. The method of claim 33, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

41. A method for treating a hepatitis virus infection in a mammal, consisting essentially of administering to said mammal a first amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



(I)

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

a second amount of an antiviral compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral compound, an immunomodulator, an immunostimulant, and mixtures thereof,

wherein said first and second amounts of said compounds together comprise an anti-hepatitis virus effective amount of said compounds.

42. The method of claim 41, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

42. The method of claim 42, wherein R is nonyl.

43. The method of claim 41, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

2025 RELEASE UNDER E.O. 14176

P-10

15

44. The method of claim 43, wherein R is nonyl.

45. The method of claim 44, wherein said alkanoyl is butanoyl.

46. The method of claim 41, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

15 *N*-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

20 *N*-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

30

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

45

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

50

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

55 *N*-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
60 *N*-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
65 *N*-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
70 *N*-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
75 *N*-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

46841=19

47. The method of claim 41, wherein said nucleoside or nucleotide antiviral compound is selected from the group consisting of:

80 (+)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine;
(-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC);
(-)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine (FTC);
(-)2',3', dideoxy-3'-thiacytidine [(-)-SddC];
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC);

1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine triphosphate (FIACTP);

85 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-methyluracil (FMAU);

1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide;

2',3'-dideoxy-3'-fluoro-5-methyl-dexocytidine (FddMeCyt);

2',3'-dideoxy-3'-chloro-5-methyl-dexocytidine (ClddMeCyt);

2',3'-dideoxy-3'-amino-5-methyl-dexocytidine (AddMeCyt);

2',3'-dideoxy-3'-fluoro-5-methyl-cytidine (FddMeCyt);

2',3'-dideoxy-3'-chloro-5-methyl-cytidine (ClddMeCyt);

2',3'-dideoxy-3'-amino-5-methyl-cytidine (AddMeCyt);

2',3'-dideoxy-3'-fluorothymidine (FddThd);

2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);

2',3'-dideoxy-beta-L-5-thiacytidine;

2',3'-dideoxy-beta-L-5-cytidine (beta-L-ddC);

9-(1,3-dihydroxy-2-propoxymethyl)guanine;

2'-deoxy-3'-thia-5-fluorocytosine;

3'-amino-5-methyl-dexocytidine (AddMeCyt);

100 2-amino-1,9-[(2-hydroxymethyl-1-(hydroxymethyl)ethoxy]methyl]-6H-purin-6-one (gancyclovir);

2-[2-(2-amino-9H-purin-9y)ethyl]-1,3-propandil diacetate (famciclovir);

2-amino-1,9-dihydro-9-[(2-hydroxy-ethoxy)methyl]6H-purin-6-one (acyclovir);

9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine (penciclovir);

105 9-(4-hydroxy-3-hydroxymethyl-but-1-yl)-6-deoxy-guanine, diacetate (famciclovir);

3'-azido-3'-deoxythymidine (AZT);

3'-chloro-5-methyl-dexocytidine (ClddMeCyt);

9-(2-phosphonyl-methoxyethyl)-2',6'-diaminopurine-2',3'-dideoxyriboside;

9-(2-phosphonylmethoxyethyl)adenine (PMEA);

110 acyclovir triphosphate (ACVTP);

D-carbocyclic-2'-deoxyguanosine (CdG);

115

dideoxy-cytidine;
dideoxy-cytosine (ddC);
dideoxy-guanine (ddG);
dideoxy-inosine (ddI);
E-5-(2-bromovinyl)-2'-deoxyuridine triphosphate;
fluoro-arabinofuranosyl-iodouracil;
1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-ido-uracil (FIAU);
stavudine;
9-beta-D-arabinofuranosyl-9H-purine-6-amine monohydrate (Ara-A);
9-beta-D-arabinofuranosyl-9H-purine-6-amine-5'-monophosphate monohydrate
(Ara-AMP);
2-deoxy-3'-thia-5-fluorocytidine;
2',3'-dideoxy-guanine; and
2',3'-dideoxy-guanosine.

120
125

5


48. The method of claim 41, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of *N*-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof, *N*-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate or a pharmaceutically acceptable salt thereof, and mixtures thereof; and

wherein said nucleoside or nucleotide antiviral compound is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC).

#318625

49. A method for treating a hepatitis B virus infection in a mammal, comprising administering to said mammal from about 0.1 mg/kg/day to about 100 mg/kg/day of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:

5



(I)

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

from about 0.1 mg/person/day to about 500 mg/person/day of a compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral compound, and a mixture thereof.

50. The method of claim 49, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

51. The method of claim 50, wherein R is nonyl.

52. The method of claim 49, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

53. The method of claim 52, wherein R is nonyl.

54. The method of claim 53, wherein said alkanoyl is butanoyl.

55. The method of claim 49, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

- 5 *N*-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
20 *N*-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
25 *N*-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995
1000

30 *N*-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
35 *N*-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
40 *N*-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
45 *N*-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
50 *N*-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
55 *N*-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

56. The method of claim 49, wherein said nucleoside or nucleotide antiviral compound is selected from the group consisting of:

(+)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine;
(-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC);
(-)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine (FTC);
(-)2',3', dideoxy-3'-thiacytidine [(-)-SddC];
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine triphosphate (FIACTP);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-methyluracil (FMAU);
1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide;

15

2',3'-dideoxy-3'-fluoro-5-methyl-dexocytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-dexocytidine (AddMeCyt);
2',3'-dideoxy-3'-fluoro-5-methyl-cytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-cytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-cytidine (AddMeCyt);
2',3'-dideoxy-3'-fluorothymidine (FddThd);
2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);
2',3'-dideoxy-beta-L-5-thiacytidine;
2',3'-dideoxy-beta-L-5-cytidine (beta-L-ddC);
9-(1,3-dihydroxy-2-propoxymethyl)guanine;
2'-deoxy-3'-thia-5-fluorocytosine;
3'-amino-5-methyl-dexocytidine (AddMeCyt);
2-amino-1,9-[(2-hydroxymethyl-1-(hydroxymethyl)ethoxy]methyl]-6H-purin-6-one
(gancyclovir);
2-[2-(2-amino-9H-purin-9y)ethyl]-1,3-propanediol diacetate (famciclovir);
2-amino-1,9-dihydro-9-[(2-hydroxy-ethoxy)methyl]6H-purin-6-one (acyclovir);
9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine (penciclovir);
30 9-(4-hydroxy-3-hydroxymethyl-but-1-yl)-6-deoxy-guanine, diacetate (famciclovir);
3'-azido-3'-deoxythymidine (AZT);
3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
9-(2-phosphonyl-methoxyethyl)-2',6'-diaminopurine-2',3'-dideoxyriboside;
9-(2-phosphonylmethoxyethyl)adenine (PMEA);
acyclovir triphosphate (ACVTP);
D-carbocyclic-2'-deoxyguanosine (CdG);
dideoxy-cytidine;
dideoxy-cytosine (ddC);
dideoxy-guanine (ddG);
40 dideoxy-inosine (ddI);

35

40

20
25
30
35
40

E-5-(2-bromovinyl)-2'-deoxyuridine triphosphate;
fluoro-arabinofuranosyl-iodouracil;
1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-ido-uracil (FIAU);
stavudine;
9-beta-D-arabinofuranosyl-9H-purine-6-amine monohydrate (Ara-A);
9-beta-D-arabinofuranosyl-9H-purine-6-amine-5'-monophosphate monohydrate
(AMP);
2-deoxy-3'-thia-5-fluorocytidine;
2',3'-dideoxy-guanine; and
2',3'-dideoxy-guanosine.


57. The method of claim 49, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of *N*-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof, *N*-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate or a pharmaceutically acceptable salt thereof, and mixtures thereof; and

wherein said nucleoside or nucleotide antiviral compound is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC).

← 58. A method for treating a hepatitis B virus infection in a human patient, comprising administering to said human patient from about 0.1 mg/kg/day to about 100 mg/kg/day of an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound selected from the group consisting *N*-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof, *N*-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate or a pharmaceutically acceptable salt thereof, and mixtures thereof, and from about 0.1 mg/person/day to about 500 mg/person/day of (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate.

10

59. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an antiviral effective amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



(I)

substantially exclusive of the administration of an antiviral composition comprising a nucleoside, a nucleotide, an immunomodulator, or an immunostimulant,

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl.

25

60. The method of claim 59, further comprising administering said at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier, excipient, or diluent.

61. The method of claim 59, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

62. The method of claim 61, wherein R is nonyl.

15
20
25

63. The method of claim 59, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

64. The method of claim 63, wherein R is nonyl.

65. The method of claim 64, wherein said alkanoyl is butanoyl.

66. The method of claim 59, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol:

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol:

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol:

N(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol

N(n-acetyl)-1,5-dideoxy-1,5-imino-D-glucitol:

N-(*n*-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol-tetrabutyrate

N(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol-tetrabutyrate

N6 = 1.5 d1 = 1.5 d1 = Radial attachment

Né le 1er juillet 1851 à Paris, il fut admis au barreau de Paris en 1875.

N1 = 1, N2 = 1.5, N3 = 1.5, α_1 = 0.1, α_2 = 0.1.

14. (Rudney), 1,3-dioxo-1,3-hydroxy-2-glutaric, tetrasubstituted,

25

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

30

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

35

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

40

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

45

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

50

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

55


N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
70 *N*-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
75 *N*-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

60
65
70
75

67. The method of claim 59, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate,

5 glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

10 68. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an antiviral effective amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



15 (I)

substantially exclusive of the administration of antiviral compounds other than compounds of Formula I,

20 wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl.

25 69. The method of claim 68, further comprising administering said at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or

pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier, excipient, or diluent.

70. The method of claim 68, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

71. The method of claim 70, wherein R is nonyl.

72. The method of claim 68, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

73. The method of claim 72, wherein R is nonyl.

74. The method of claim 73, wherein said alkanoyl is butanoyl.

75. The method of claim 68, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

5

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

10

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

15 *N*-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate
 N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
20 *N*-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
35 *N*-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
40 *N*-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
45 N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
50 N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
55 N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
60 N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
65 N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
70 N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

***N*-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;**


N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

75

76. The method of claim 68, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

77. A pharmaceutical composition, comprising an antiviral effective amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



15

(I)

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

20

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

a pharmaceutically acceptable carrier, excipient, or diluent.

78. The pharmaceutical composition of claim 77, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

79. The pharmaceutical composition of claim 78, wherein R is nonyl.

80. The pharmaceutical composition of claim 77, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

81. The pharmaceutical composition of claim 80, wherein R is nonyl.

82. The pharmaceutical composition of claim 81, wherein said alkanoyl is butanoyl.

83. The pharmaceutical composition of claim 77, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

5

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

10

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

15 *N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;*
N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
20 *N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;*
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
25 *N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;*
N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
30 *N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;*
N-(2ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
35 *N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;*
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
40 *N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;*
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

- 45 *N*-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
50 *N*-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
55 *N*-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
60 *N*-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
65 *N*-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
70 *N*-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;


75

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

84. The pharmaceutical composition of claim 77, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

85. A pharmaceutical composition, consisting essentially of an antiviral effective amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:

5



(I)

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

10 wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and
a pharmaceutically acceptable carrier, diluent, or excipient.

86. The pharmaceutical composition of claim 85, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

87. The pharmaceutical composition of claim 86, wherein R is nonyl.

88. The pharmaceutical composition of claim 85, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

89. The pharmaceutical composition of claim 88, wherein R is nonyl.

90. The pharmaceutical composition of claim 89, wherein said alkanoyl is butanoyl.

91. The pharmaceutical composition of claim 85, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

5 N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

10 N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
15 *N*-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
20 *N*-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
25 *N*-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
30 *N*-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
35 *N*-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
40 *N*-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

45

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

50

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

55

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

60

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

65

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

70

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;


N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

75

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

92. The method of claim 85, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentane~~propionate~~, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

93. A pharmaceutical composition, comprising an antiviral effective amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



5

(I)

substantially free of a nucleoside, nucleotide, immunomodulator, or immunostimulant,

10 wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and
a pharmaceutically acceptable, carrier, diluent, or excipient.

94. The pharmaceutical composition of claim 93, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

95. The pharmaceutical composition of claim 94, wherein R is nonyl.

96. The pharmaceutical composition of claim 93, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

97. The pharmaceutical composition of claim 96, wherein R is nonyl.

98. The pharmaceutical composition of claim 97, wherein said alkanoyl is butanoyl.

99. The pharmaceutical composition of claim 93, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

5 N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

10 *N*-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
15 *N*-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate
20 *N*-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
25 *N*-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
30 *N*-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
35 *N*-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

- 40 *N*-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
45 *N*-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
50 *N*-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
60 *N*-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
65 *N*-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

70


N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

75

100. The pharmaceutical composition of claim 93, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

10

101. A pharmaceutical composition, comprising an antiviral effective amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



15

(I)

substantially free of antiviral compounds other than compounds of Formula I,
wherein R is selected from the group consisting of straight chain alkyl having a
chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the
main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

20 wherein W, X, Y and Z are each independently selected from the group consisting
of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and
a pharmaceutically acceptable, carrier, diluent, or excipient.

102. The pharmaceutical composition of claim 101, wherein R is straight chain
alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

103. The pharmaceutical composition of claim 102, wherein R is nonyl.

104. The pharmaceutical composition of claim 101, wherein R is straight chain
alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

105. The pharmaceutical composition of claim 104, wherein R is nonyl.

106. The pharmaceutical composition of claim 105, wherein said alkanoyl is
butanoyl.

107. The pharmaceutical composition of claim 101, wherein said N-substituted-
1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

5

10

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

15

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

20

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

25

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

30

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

35

N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

40

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

45

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

50

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

55

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

60

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

65

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate:

70 N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol:

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol:

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol:


N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol tetraacetate:

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol

108. The pharmaceutical composition of claim 101, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

— 109. A composition, comprising at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



40

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
55 *N*-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
60 *N*-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
65 *N*-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

55

60

65

45

50

10 *N*-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate
 N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

5

(I)

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

10 wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

an antiviral compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral compound, an immunomodulator, an immunostimulant, and mixtures thereof.

110. The composition of claim 109, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

111. The composition of claim 110, wherein R is nonyl.

112. The composition of claim 109, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

113. The composition of claim 112, wherein R is nonyl.

114. The composition of claim 113, wherein said alkanoyl is butanoyl.

115. The composition of claim 109, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

5 N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

70

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

75
80
85
90
95

116. The composition of claim 109, wherein said nucleoside or nucleotide antiviral compound is selected from the group consisting of:

10

(+)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine;
(-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC);
(-)cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine (FTC);
(-)-2',3', dideoxy-3'-thiacytidine [(-)-SddC];
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine triphosphate
(FIACTP);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-methyluracil (FMAU);
1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide;
2',3'-dideoxy-3'-fluoro-5-methyl-dexocytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-dexocytidine (AddMeCyt);
2',3'-dideoxy-3'-fluoro-5-methyl-cytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-cytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-cytidine (AddMeCyt);
2',3'-dideoxy-3'-fluorothymidine (FddThd);
15

20 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);
 2',3'-dideoxy-beta-L-5-thiacytidine;
 2',3'-dideoxy-beta-L-5-cytidine (beta-L-ddC);
 9-(1,3-dihydroxy-2-propoxymethyl)guanine;
 2'-deoxy-3'-thia-5-fluorocytosine;
 3'-amino-5-methyl-dexocytidine (AddMeCyt);
25 2-amino-1,9-[(2-hydroxymethyl-1-(hydroxymethyl)ethoxy]methyl]-6H-purin-6-one
(gancyclovir);
 2-[2-(2-amino-9H-purin-9y)ethyl]-1,3-propandil diacetate (famciclovir);
 2-amino-1,9-dihydro-9-[(2-hydroxy-ethoxy)methyl]6H-purin-6-one (acyclovir);
 9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine (penciclovir);
 9-(4-hydroxy-3-hydroxymethyl-but-1-yl)-6-deoxy-guanine, diacetate (famciclovir);
 3'-azido-3'-deoxythymidine (AZT);
 3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
 9-(2-phosphonyl-methoxyethyl)-2',6'-diaminopurine-2',3'-dideoxyriboside;
 9-(2-phosphonylmethoxyethyl)adenine (PMEA);
 acyclovir triphosphate (ACVTP);
 D-carbocyclic-2'-deoxyguanosine (CdG);
 dideoxy-cytidine;
 dideoxy-cytosine (ddC);
 dideoxy-guanine (ddG);
40 dideoxy-inosine (ddI);
 E-5-(2-bromovinyl)-2'-deoxyuridine triphosphate;
 fluoro-arabinofuranosyl-iodouracil;
 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-iodo-uracil (FIAU);
 stavudine;
45 9-beta-D-arabinofuranosyl-9H-purine-6-amine monohydrate (Ara-A);
 9-beta-D-arabinofuranosyl-9H-purine-6-amine-5'-monophosphate monohydrate
(Ara-AMP);

50

2-deoxy-3'-thia-5-fluorocytidine;

2',3'-dideoxy-guanine; and

2',3'-dideoxy-guanosine.


117. The composition of claim 109, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of *N*-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof, *N*-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate or a pharmaceutically acceptable salt thereof, and mixtures thereof; and

wherein said nucleoside or nucleotide antiviral compound is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC).

(36) 118. A pharmaceutical composition, comprising:

a first amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:

5



(I)

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

10 wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl;

a second amount of an antiviral compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral compound, an immunomodulator, and immunostimulant, and mixtures thereof; and

15 a pharmaceutically acceptable carrier, diluent, or excipient,
 wherein said first and second amounts of said compounds together comprise an
 antiviral effective amount of said compounds.

119. The pharmaceutical composition of claim 118, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

120. The pharmaceutical composition of claim 119, wherein R is nonyl.

121. The pharmaceutical composition of claim 118, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

122. The pharmaceutical composition of claim 121, wherein R is nonyl.

123. The pharmaceutical composition of claim 122, wherein said alkanoyl is butanoyl.

124. The pharmaceutical composition of claim 118, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

10 *N*-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
15 *N*-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate
20 *N*-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
30 *N*-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
35 *N*-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
40 N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
45 N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
50 N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
55 N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
60 N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
65 N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

70

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

75

125. The pharmaceutical composition of claim 118, wherein said nucleoside or nucleotide antiviral compound is selected from the group consisting of:

5

(+)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine;
(-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC);
(-)cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine (FTC);
(-)-2',3', dideoxy-3'-thiacytidine [(-)-SddC];
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine triphosphate
(FIACTP);
10 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-methyluracil (FMAU);
1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide;
2',3'-dideoxy-3'-fluoro-5-methyl-dexocytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-dexocytidine (AddMeCyt);
15 2',3'-dideoxy-3'-fluoro-5-methyl-cytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-cytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-cytidine (AddMeCyt);
2',3'-dideoxy-3'-fluorothymidine (FddThd);
2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);
20 2',3'-dideoxy-beta-L-5-thiacytidine;

2',3'-dideoxy-beta-L-5-cytidine (beta-L-ddC);
9-(1,3-dihydroxy-2-propoxymethyl)guanine;
2'-deoxy-3'-thia-5-fluorocytosine;
3'-amino-5-methyl-dexocytidine (AddMeCyt);
25 2-amino-1,9-[(2-hydroxymethyl-1-(hydroxymethyl)ethoxy]methyl]-6H-purin-6-one
(gancyclovir);
2-[2-(2-amino-9H-purin-9y)ethyl]-1,3-propandil diacetate (famciclovir);
2-amino-1,9-dihydro-9-[(2-hydroxy-ethoxy)methyl]6H-purin-6-one (acyclovir);
30 9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine (penciclovir);
9-(4-hydroxy-3-hydroxymethyl-but-1-yl)-6-deoxy-guanine, diacetate (famciclovir);
3'-azido-3'-deoxythymidine (AZT);
3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
9-(2-phosphonyl-methoxyethyl)-2',6'-diaminopurine-2',3'-dideoxyriboside;
9-(2-phosphonylmethoxyethyl)adenine (PMEA);
acyclovir triphosphate (ACVTP);
D-carbocyclic-2'-deoxyguanosine (CdG);
35 dideoxy-cytidine;
dideoxy-cytosine (ddC);
dideoxy-guanine (ddG);
dideoxy-inosine (ddI);
40 E-5-(2-bromovinyl)-2'-deoxyuridine triphosphate;
fluoro-arabinofuranosyl-iodouracil;
1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-iodo-uracil (FIAU);
stavudine;
45 9-beta-D-arabinofuranosyl-9H-purine-6-amine monohydrate (Ara-A);
9-beta-D-arabinofuranosyl-9H-purine-6-amine-5'-monophosphate monohydrate
(Ara-AMP);
2-deoxy-3'-thia-5-fluorocytidine;
2',3'-dideoxy-guanine; and

50

2',3'-dideoxy-guanosine.

126. The pharmaceutical composition of claim 118, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of *N*-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof, *N*-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate or a pharmaceutically acceptable salt thereof, and mixtures thereof; and

5


wherein said nucleoside or nucleotide antiviral compound is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC).

66

127. A pharmaceutical composition for treating a hepatitis B virus infection in a mammal, comprising:

from about 0.1 mg to about 100 mg of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:

5



(I)

10

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl;

15

from about 0.1 mg to about 500 mg of a compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral, and mixtures thereof; and

a pharmaceutically acceptable carrier, diluent, or excipient.

128. The pharmaceutical composition of claim 127, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

129. The pharmaceutical composition of claim 128, wherein R is nonyl.

130. The pharmaceutical composition of claim 127, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

131. The pharmaceutical composition of claim 130, wherein R is nonyl.

132. The pharmaceutical composition of claim 131, wherein said alkanoyl is butanoyl.

133. The pharmaceutical composition of claim 127, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

5 N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

10

N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

00024962626160224200

N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
15 N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
20 N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
25 N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
30 N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
35 N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
40 N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

20
25
30
35
40

45

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
50 *N*-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
55 *N*-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
60 *N*-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

60

65

70 *N*-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;
 N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
75 *N*-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

134. The pharmaceutical composition of claim 127, wherein said nucleoside or nucleotide antiviral compound is selected from the group consisting of:

(+)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine;
(-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC);
(-)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine (FTC);
(-)2',3', dideoxy-3'-thiacytidine [(-)-SddC];
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine triphosphate
(FIACTP);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-methyluracil (FMAU);
1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide;
2',3'-dideoxy-3'-fluoro-5-methyl-dexocytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-dexocytidine (AddMeCyt);
15 2',3'-dideoxy-3'-fluoro-5-methyl-cytidine (FddMeCyt);
 2',3'-dideoxy-3'-chloro-5-methyl-cytidine (ClddMeCyt);
 2',3'-dideoxy-3'-amino-5-methyl-cytidine (AddMeCyt);
 2',3'-dideoxy-3'-fluorothymidine (FddThd);
 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);
20 2',3'-dideoxy-beta-L-5-thiacytidine;
 2',3'-dideoxy-beta-L-5-cytidine (beta-L-ddC);
 9-(1,3-dihydroxy-2-propoxymethyl)guanine;

25

2'-deoxy-3'-thia-5-fluorocytosine;
3'-amino-5-methyl-dexocytidine (AddMeCyt);
2-amino-1,9-[(2-hydroxymethyl-1-(hydroxymethyl)ethoxy]methyl]-6H-purin-6-one
(gancyclovir);

30

2-[2-(2-amino-9H-purin-9y)ethyl]-1,3-propandil diacetate (famciclovir);
2-amino-1,9-dihydro-9-[(2-hydroxy-ethoxy)methyl]6H-purin-6-one (acyclovir);
9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine (penciclovir);
9-(4-hydroxy-3-hydroxymethyl-but-1-yl)-6-deoxy-guanine, diacetate (famciclovir);
3'-azido-3'-deoxythymidine (AZT);
3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
9-(2-phosphonyl-methoxyethyl)-2',6'-diaminopurine-2',3'-dideoxyriboside;
9-(2-phosphonylmethoxyethyl)adenine (PMEA);
acyclovir triphosphate (ACVTP);
D-carbocyclic-2'-deoxyguanosine (CdG);
dideoxy-cytidine;

35

dideoxy-cytosine (ddC);
dideoxy-guanine (ddG);
dideoxy-inosine (ddI);
E-5-(2-bromovinyl)-2'-deoxyuridine triphosphate;
fluoro-arabinofuranosyl-iodouracil;
1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-iodo-uracil (FIAU);
stavudine;
40
45
9-beta-D-arabinofuranosyl-9H-purine-6-amine monohydrate (Ara-A);
9-beta-D-arabinofuranosyl-9H-purine-6-amine-5'-monophosphate monohydrate
(Ara-AMP);
2-deoxy-3'-thia-5-fluorocytidine;
2',3'-dideoxy-guanine; and
2',3'-dideoxy-guanosine.

50

5

135. The pharmaceutical composition of claim 127, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of *N*-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof, *N*-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate or a pharmaceutically acceptable salt thereof, and mixtures thereof; and

wherein said nucleoside or nucleotide antiviral compound is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC).


136. A pharmaceutical composition for treating a hepatitis B virus infection in a human patient, comprising:

from about 0.1 mg to about 100 mg of an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound selected from the group consisting of *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof, *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate or a pharmaceutically acceptable salt thereof, and mixtures thereof:

from about 0.1 mg to about 500 mg of (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate; and

10 a pharmaceutically acceptable carrier, diluent, or excipient.

137. A salt, comprising an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I:



wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

10 wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

a compound selected from the group consisting of a nucleoside having an acidic moiety and a nucleotide.

138. The salt of claim 137, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

139. The salt of claim 138, wherein R is nonyl.

140. The salt of claim 137, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

141. The salt of claim 140, wherein R is nonyl.

142. The salt of claim 141, wherein said alkanoyl is butanoyl.

143. The salt of claim 137, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

5 N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

10 *N*-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
15 *N*-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate
20 *N*-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
25 *N*-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
30 *N*-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
35 *N*-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

40 *N*-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
45 *N*-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
 N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
60 *N*-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
 N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
65 *N*-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

70 *N*-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

75 *N*-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

144. The salt of claim 137, wherein said nucleoside having an acidic moiety is selected from the group consisting of compounds of Formula II, III, IV, V, and VI.

145. The salt of claim 137, wherein said nucleotide is selected from the group consisting of compounds of Formula II, III, IV, V, and VI.

146. The salt of claim 145, wherein said nucleotide is selected from the group consisting of:

(-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC);

5 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine triphosphate (FIACTP);

acyclovir triphosphate (ACVTP);

E-5-(2-bromovinyl)-2'-deoxyuridine triphosphate; and

9-beta-D-arabinofuranosyl-9H-purine-6-amine-5'-monophosphate monohydrate (Ara-AMP).

147. The salt of claim 137, wherein:

said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of *N*-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol and *N*-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate; and

5 said nucleotide is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate.

148. A method, comprising reacting *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol and (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate under salt-forming conditions.

149. A salt formed by the method of claim 148.